Involvement of a cranial nerve caries a poor prognosis for many malignancies. Recurrent or residual disease in the trigeminal or facial nerve after primary therapy poses a challenge due to the location of the nerve in the skull base, the proximity to the brain, brainstem, cavernous sinus, and optic apparatus and the resulting complex geometry. Surgical resection caries a high risk of morbidity and is often not an option for these patients. Stereotactic radiosurgery and radiotherapy are potential treatment options for patients with cancer involving the trigeminal or facial nerve. These techniques can deliver high doses of radiation to complex volumes while sparing adjacent critical structures. In the current study, seven cases of cancer involving the trigeminal or facial nerve are presented. These patients had unresectable recurrent or residual disease after definitive local therapy. Each patient was treated with stereotactic radiation therapy using a linear accelerator based system. A multidisciplinary approach including neuroradiology and surgical oncology was used to delineate target volumes. Treatment was well tolerated with no acute grade 3 or higher toxicity. One patient who was reirradiated experienced cerebral radionecrosis with mild symptoms. Four of the seven patients treated had no evidence of disease after a median follow up of 12 months (range 2-24 months). A dosimetric analysis was performed to compare intensity modulated fractionated stereotactic radiation therapy (IM-FSRT) to a 3D conformal technique. The dose to 90% (D90) of the brainstem was lower with the IM-FSRT plan by a mean of 13.5 Gy. The D95 to the ipsilateral optic nerve was also reduced with IM-FSRT by 12.2 Gy and the D95 for the optic chiasm was lower with FSRT by 16.3 Gy. Treatment of malignancies involving a cranial nerve requires a multidisciplinary approach. Use of an IM-FSRT technique with a micro-multileaf collimator resulted in a lower dose to the brainstem, optic nerves and chiasm for each case examined.
Introduction
Perineural invasion of malignant tumors is associated with decreased survival rates and a poor prognosis (1). Perineural spread along the cranial nerves is commonly seen in head and neck squamous cell carcinoma, adenoid cystic carcinoma, and lymphoma. Additionally, certain tumors, such as a malignant peripheral nerve sheath tumor, can originate from a cranial nerve (2) .
The trigeminal nerve is the largest of the cranial nerves. The trigeminal ganglion is located near the apex of the petrous portion of the temporal bone. It is in close proximity to the internal carotid artery and the cavernous sinus. The trigeminal ganglion has three major branches. The ophthalmic (V1) and maxillary (V2) branches consist of sensory fibers. The mandibular (V3) branch has a sensory and a motor component. V1 exits the skull base through the superior orbital fissure. V2 exits through foramen rotundum and V3 exits through foramen ovale. The major branches of V1 include the superior orbital nerve. The major branches of V2 are the infraorbital, superior alveolar, the greater and lesser palatine, and the nasopalatine nerves. The major branches of V3 include the auriculotemporal, lingual, and inferior alveolar nerves.
The facial nerve innervates the muscles of the face, provides autonomic innervation to the salivary glands, and is involved in the senses of hearing and taste. The facial nerve exists the brainstem from the cerebellopontine angle into the internal auditory canal. It travels laterally to the geniculate ganglion. The facial nerve has a complex course through the petrous temporal bone before exiting through the stylomastoid foramen. After exiting the foramen, the facial nerve travels through the parotid gland and divides into its major branches.
Surgical treatment of cancer involving a cranial nerve is challenging due to the location of the nerve in the skull base and the complex anatomy. In many cases, the normal anatomy is distorted by the tumor or prior surgical intervention. Radiotherapeutic treatment of cancer involving the trigeminal or facial nerve is difficult, given the need to deliver adequate dose to the target while minimizing dose to adjacent critical structures including the brainstem, optic chiasm and nerves, and brain.
In the current study, seven cases are presented in which intensity modulated fractionated stereotactic radiotherapy was used to treat cancer involving a portion of the trigeminal nerve or the facial nerve. These cases illustrate the challenges associated with treating cancer involving a cranial nerve. A dosimetric analysis was performed to explore the potential benefit of using highly conformal intensity modulated stereotactic radiotherapy versus conventional 3D techniques. This retrospective review was approved by the Institutional Review Board at Duke University.
Cases

Case 1 Involvement of the Ophthalmic Branch of the Trigeminal Nerve
A 64-year-old male was treated with surgery alone for a squamous cell carcinoma of the right forehead. Three years later the patient presented with right facial numbness and ptosis. MRI revealed an area of enhancement in the right supraorbital nerve which extended posteriorly through the superior orbital fissure into the right cavernous sinus. On examination the patient had right eye ptosis, a dilated and unresponsive right pupil, and palsy of the extraocular muscles. A biopsy was obtained which confirmed recurrent squamous cell carcinoma and a course of fractionated stereotactic radiotherapy was recommended. Given the close proximity to the right optic nerve the patient was counseled about the potential for vision loss in the right eye.
The clinical target volume (CTV) included the course of the right trigeminal nerve starting from the ganglion, following the ophthalmic branch along the wall of the cavernous sinus, through the superior orbital foramen, along the path of supraorbital nerve (Figure 2 .1). The CTV was expanded by 2 mm for the planning target volume (PTV). An 8-field non-coplanar intensity modulated fractionated stereotactic radiotherapy (IM-FSRT) plan was created. 56 Gy in 2 Gy daily fractions was prescribed. The right optic nerve received a maximum dose of 58.9 Gy and a mean dose of 47.2 Gy. The optic chiasm had a maximum and mean dose of 37.9 and 19.4 Gy, and the brainstem had a maximum and mean dose of 55.7 and 7.9 Gy, respectively. 95% of the PTV received greater than 55 Gy.
During the course of treatment the patient experienced mild nausea which was managed with a low dose of dexamethasone. Sixteen months following radiation he was found to have widespread metastatic disease, including recurrent disease in the right trigeminal nerve.
Case 2 Malignant Peripheral Nerve Sheath Tumor Involving the Maxillary Branch of the Trigeminal Nerve
A 60-year-old male presented with a one year history of right-sided facial numbness. An MRI revealed enhancement within the maxillary branch of the right trigeminal nerve and the right pterygopalatine fossa. A biopsy was obtained and pathology was consistent with a malignant peripheral nerve sheath tumor. On examination the patient had parathesia in the maxillary distribution of the right trigeminal nerve in addition to lateral gaze nystagmus. Given the extent of disease, surgery was not feasible. A course of fractionated stereotactic radiotherapy was recommended.
The CTV covered the course of the maxillary branch of the right trigeminal nerve as it exited from the ganglion through the cavernous sinus continuing along the infraorbital nerve to the infraorbital rim ( Figure 2 .2). The CTV was expanded by 1.5 mm for the PTV. 60 Gy in 2 Gy daily fractions was prescribed and an 8-field non-coplanar IM-FSRT plan was created. The right optic nerve was well-spared, receiving a maximum dose of 45.1 Gy and a mean dose of 26.7 Gy. The right eye received a maximum dose of 52.5 Gy with 90% receiving less than 30 Gy. The brainstem received a maximum dose of 58.1 Gy with a mean dose of 9.5 Gy.
Treatment was well tolerated with no reported acute side effects. The patient was placed on low dose dexamethasone for the final two weeks to minimize edema. After 24 months of follow up the patient is radiographically and clinically stable.
Case 3 Involvement of the Trigeminal Ganglion and Pterygopalatine Canal
A 66-year-old male with desmoplastic melanoma of the lower lip was treated with surgery followed by adjuvant radiation therapy to the surgical bed and regional lymphatics. Two years later, the patient presented with numbness in his left face. MRI of the brain showed tumor involvement of the left trigeminal ganglion with disease extending into the pterygopalatine canal. On examination the patient had decreased sensation in the distribution of V2 and V3. Surgery was not an option given the extent of disease. A course of intensity modulated radiosurgery was recommended. The CTV included the proximal portion of the left trigeminal ganglion, the pterygopalatine fossa, part of the cavernous sinus, and the superior portion of the pterygopalatine canal (Figure 2 .3). The CTV was expanded by 3 mm for the PTV. 25 Gy in 5 Gy daily fractions was prescribed and a 7-field non-coplanar intensity modulated stereotactic radiosurgery (IM-SRS) plan was created. The left optic nerve and optic chiasm received maximum doses of 7.2 and 5.8 Gy, respectively. The brainstem received a maximum dose of 24.9 Gy with 99% receiving less than 12.5 Gy. The PTV received a minimum dose of 24.98 Gy with a 107% maximal dose.
The treatment was well tolerated with no acute side effects. The patient was placed on a low dose of dexamethasone for Figure 2 : Representative radiation planning images for cases 1 through 6. The green translucent volume represents the planning target volume. The yellow, red, blue, and magenta lines represent the 100%, 90%, 80%, and 50% isodose lines, respectively. two weeks. The patient was clinically and radiographically stable until 9 months after treatment when an MRI showed evidence of recurrent disease.
Case 4 Involvement of the Maxillary Branch and the Infraorbital Nerve
A 51-year-old male presented with a nodule on his right cheek and numbness along the left nasal ala. A biopsy was obtained and pathology was consistent with an adnexal carcinoma. The patient underwent radical resection. Pathology showed extensive perineural invasion of the infraorbital nerve with positive margins. A postoperative MRI revealed contiguous enhancement of the right infraorbital nerve. Physical examination was notable for decreased light touch sensation along the right V2 distribution. A course of adjuvant radiation therapy was recommended.
The CTV included the path of the infraorbital nerve from the infraorbital foramen to the trigeminal ganglion ( Figure 2 .4). The CTV was expanded by 2-3 mm to create the PTV. 60 Gy in 2 Gy daily fractions was prescribed and a 7-field noncoplanar IM-FSRT plan was created. The right optic nerve and chiasm received a maximum dose of 30.6 Gy and 22.8 Gy, respectively. The right temporal lobe received a maximum dose of 64.9 Gy and a mean dose of 15.1 Gy. The minimum dose to the PTV was 54.99 Gy and 95% of the PTV received at least 60 Gy.
The treatment was well-tolerated with no reported acute side effects. After 20 months of follow up the patient had no signs of tumor recurrence, was working full time, and had no significant neurologic deficits.
Case 5 Recurrence in Pterygopalatine Fossa
A 50-year-old female presented with a several month history of sinus congestion, left facial pain, and headaches. An MRI showed a heterogeneously enhancing mass extending from the right paranasal sinuses into the left temporal fossa. Biopsy revealed a poorly differentiated carcinoma. She underwent a partial surgical resection. Postoperative MRI showed residual disease in the medial left temporal fossa extending into the cavernous sinus, left ethmoid air cells, and the left maxillary sinus. On physical examination the patient had diplopia with leftward gaze, and mild numbness in the V2 distribution. She was treated with adjuvant radiation therapy with concurrent chemotherapy. She received a total dose of 64 Gy in 2 Gy daily fractions.
Ten months later the patient was found to have an enlarging mass in the left sphenoid sinus and middle cranial fossa involving branches of V2 and V3. She underwent a subtotal resection of the left sphenoid skull base tumor and a near total resection of the tumor in the pterygomaxillary fissure. The patient was evaluated for radiation therapy. Given her prior treatment to this area she was counseled about the substantial risk for radionecrosis.
The CTV included the left sphenoid sinus, middle cranial fossa, and surgical bed in the base of skull (Figure 2.5 ). An IM-SRS plan was generated and 25 Gy in 5 Gy daily fractions was prescribed. The left optic nerve received a maximum dose of 21.5 Gy and a mean dose of 12.6 Gy. 95% of the brainstem received less than 15 Gy with a maximum point dose of 26.4 Gy. The optic chiasm received a maximum dose of 12.7 Gy.
The treatment was well-tolerated with no reported acute side effects. The patient had improvement in her facial pain following radiosurgery. Six months following IM-SRS, an MRI showed increased enhancement in the left middle and infratemporal fossa and the left pons near the dorsal root entry zone of the left trigeminal nerve. The patient underwent craniotomy and biopsy showed radionecrosis with no evidence of disease. Three months later she had another biopsy and was found to have disease in her left cranial sinus.
Case 6 Recurrence in Meckel's Cave and Foramen Ovale
An 81-year-old male presented with a left cranial nerve VII palsy. MRI showed enhancement of left cranial nerve VII and a left parotid mass. A biopsy was obtained and pathology showed squamous cell carcinoma. The patient underwent surgical resection followed by adjuvant radiation therapy. The parotid bed received a total dose of 60 Gy. The left cranial nerve VII remnant received 40 Gy followed by an SRS boost of 13 Gy. An MRI 3 months later showed perineural spread along the left trigeminal nerve in addition to a soft tissue mass filling Meckel's cave and foramen ovale. Surgery was not an option given the location of the lesion. The risks of reirradiation were discussed and the patient elected to proceed.
The CTV included the area of abnormality seen on the MRI (Figure 2 .6). 45 Gy in 1.8 Gy daily fractions was prescribed. A 6-field non-coplanar IM-FSRT plan was created. There was a small amount of overlap with the patient's prior treatment fields. A small portion of the temporal lobe received a cumulative dose of 93 Gy. The left optic nerve and chiasm received a maximum dose of 14.9 Gy and 35.3 Gy respectively. The brainstem received a maximum dose of 45.4 Gy. The mandible received a maximum dose of 43.2 Gy.
The treatment was well tolerated with no acute grade 3 toxicity. Five months after radiation therapy, the patient was clinically and radiographically stable with no reported toxicity. 
Case 7 Recurrence in the Facial Nerve
A 64-year-old male presented with left facial pain. Examination revealed a left parotid tumor. The patient underwent parotidectomy and lymph node dissection. Pathology found adenocarcinoma with multiple positive lymph nodes. The patient was treated with adjuvant chemoradiation therapy. Ten months later, an MRI was concerning for tumor recurrence in the left facial nerve. The patient underwent a mastiodectomy with biopsy of the facial nerve. Pathology showed adenocarcinoma in the facial nerve with positive margins. A course of SRS to the facial nerve was recommended.
The CTV included the course of the facial nerve from the brainstem through the base of skull and petrous temporal bone (Figure 3 ). Because of his prior treatments the resection bed was difficult to identify on imaging. The neurootolaryngologist who performed the mastoidectomy was able to precisely identify and help contour the tumor bed.
The prior treatment plan was reviewed and care was made to minimize overlap between the two plans. A 6-field noncoplanar IM-SRS plan was generated. A total dose of 25 Gy in 5 Gy daily fractions was prescribed. The brainstem received a maximum and mean dose of 22.5 Gy and 1.6 Gy, respectively. The optic chiasm received a maximum dose of 3.6 Gy and a mean dose of 1.1 Gy.
The patient experienced no acute side effects. Four months after treatment, the patient was doing well with mild to moderate xerostomia. Imaging showed enhancement of the nerve consistent with a treatment effect.
Treatment Planning and Dosimetry
Treatment Planning
All patients underwent CT simulation in a thermoplastic cranial U-frame mask (BrainLAB AG, Munich, Germany).
Figure 3:
Representative radiation planning images for case 7. The green translucent volume represents the planning target volume. The yellow, red, blue, and magenta lines represent the 100%, 90%, 80%, and 50% isodose lines, respectively. CT images were fused with a thin slice MRI often with fat saturation using iPlan software (BrainLAB). Normal tissue structures including the brain, brainstem, eyes, optic nerves, chiasm, and spine were contoured. The clinical target volumes were delineated using the assistance of a neuroradiologist and/or surgeon. To create the PTV, the CTV was expanded by 1 to 3 mm depending on the proximity to critical structures. Treatment plans using intensity modulated fractionated stereotactic radiation therapy were created using iPlan and Eclipse planning software (BrainLAB and Varian). Radiation dose was typically prescribed to the 95% to 100% isodose line with a homogenous dose prescription.
Patients were treated using a Novalis Tx radiosurgery system (Varian) with a high definition micro-multileaf collimator. Previously, we showed that the fine leaf thickness (2.5 mm at isocenter) offered dosimetric advantages over a conventional 5 mm leaf width collimator for radiosurgical treatment of a variety of anatomic sites (3). Daily orthogonal kV imaging (ExacTrac, BrainLAB, OBI, Varian Medical Systems) was used to verify set up. Cone beam CT was used daily for plans with five or fewer fractions and once or twice weekly for hyperfractionated regimens.
Dosimetric Analysis
A dosimetric analysis of different treatment techniques was performed for the first four cases. A 3D conformal plan was created for each case and compared to an intensity modulated FSRT plan with and without a high definition micro-multileaf collimator (5 mm versus 2.5 mm leaf width at isocenter).
The target volumes described in the cases and are shown in Figures 3 and 4 . The treatment volumes include the involved branches of the trigeminal and facial nerve and the skull base. The CTV was expanded by 1-3 mm for the PTV, depending on the proximity to the brainstem and optic apparatus. Each plan was created with Eclipse planning software using the same target volumes and normal tissue contours in each case.
The dose volume histograms generated from the IM-FSRT plans were more favorable for each structure analyzed in each case. The structures receiving the highest and most clinically relevant dose were the ipsilateral optic nerve, optic chiasm, and brainstem. Compared to a 3D conformal technique, the maximum dose to 90% (D90) of the brainstem was lower with the IM-FSRT plan by a mean dose of 13.5 Gy (Table I) . The D95 to the ipsilateral optic nerve was reduced by a mean dose of 12.2 Gy with IM-FSRT. The D95 for the optic chiasm was lower with the IM-FSRT plan by a mean dose of 16.3 Gy. Use of a high-definition multi-leaf collimator resulted in a small decrease in dose to all critical structures in each case compared to a conventional collimator.
Discussion
The cases presented demonstrate the complex anatomy of the trigeminal and facial nerves and the challenges associated with delivering an adequate dose of radiation to these targets (4). When treating this patient population it is important to utilize a multidisciplinary team. Communication between otolaryngologists, neuro-ophthalmologic surgeons, neurosurgeons, pathologists, and neuroradiologists is critical to delineate appropriate target volumes. Thin slice MRI with base of skull/cranial nerve specific protocols is often necessary to determine which segments are involved (5). Despite the best imaging available, microscopic involvement below the resolution of MRI requires appropriate coverage of the proximal and distal segments of the nerve, as dictated by clinical judgment. A thorough understanding of the course of the cranial nerve, the anatomic functional correlates, and base of skull anatomy, as well as the capabilities and limitations of the specific treatment planning software and stereotactic radiotherapy system, is required for these cases.
Approximately 60 Gy in 2 Gy daily fractions is recommended to treat microscopic disease in head and neck squamous cell carcinoma (6). This dose exceeds the tolerance limit of several structures including the optic nerve and chiasm and the brainstem. Dose tolerance limits for these structures are summarized in the QUANTEC series of publications (7-12). Effective immobilization and accurate set up is vitally important for these cases. By using a rigid thermoplastic mask and daily localization with orthogonal imaging and periodic cone beam CT, we are typically able to minimize our CTV to PTV expansion to 1-3 mm.
There are limited reports regarding the use of fractionated radiation to treat cancer involving the trigeminal and facial nerves. Most of the data on treatment of the trigeminal nerve is for trigeminal neuralgia which is a benign condition and typically involves single fraction radiosurgery (13, 14) . With perineural invasion, a large portion of the nerve tract is at risk and single fraction radiosurgery is not feasible for these cases. Despite delivering relatively high doses of radiation to the nerves, local/in field recurrence was seen in three of our seven patients, one of these patients developed disseminated disease throughout the craniospinal axis. Four of the seven patients treated had no evidence of disease after a median follow up of 12 months (range 2-24 months). The most serious complication seen was radionecrosis (case 5) requiring craniotomy to rule out recurrence. This occurred in a patient who was previously treated. Interestingly, this patient reported an improvement in her pain after retreatment and was relatively asymptomatic from her radionecrosis.
Advances in radiation therapy treatment planning and delivery may allow for dose escalation in the future. The trigeminal Technology in Cancer Research & Treatment, Volume 11, Number 3, June 2012 nerve can tolerate high doses of radiation. Data from nonhuman primates suggest the trigeminal nerve can tolerate up to 100 Gy in a single fraction (15). Several reports indicate a high functional preservation rate in humans following doses in the 80-90 Gy range (16). With more conformal techniques dose escalation has the potential to increase local control while maintaining function of the nerve.
In conclusion, treatment of a cranial nerve with high dose radiation therapy is challenging and requires a multidisciplinary approach. Use of highly conformal techniques may reduce dose to critical structures. In the small cohort presented here, several patients appeared to benefit from treatment with FSRT.
Table I
Dosimetric comparison between intensity modulated FSRT with or without a high definition micro-multileaf collimator (2.5 mm versus 5 mm leaf width at isocenter) and a 3D conformal technique (n 5 4). Identical target volumes and expansions were used for each plan on each case. D95 means 95% of the volume receives less than the reported dose. 
